The Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial

This analysis of ADVANCE trial data (n=11,071) found the benefits of intensive glycaemic control in terms of major vascular events and all-cause mortality, and the increased risk of severe hypoglycaemia, did not differ according to baseline level of cardiovascular risk or HbA1c.


Diabetes Care